论文部分内容阅读
美国国家卫生研究院一个咨询委员会批准了首个利用被誉为“基因剪刀”的CRISPR基因编辑技术来治疗癌症的人体临床试验,让这种目前备受关注的生物医学技术在美国距临床试验仅差美国食品和药物管理局批准一步之遥。美国国家卫生研究院“重组DNA咨询委员会”批准了这项由美国宾夕法尼亚大学提交的临床试验计划。该委员会负责对在美国进行的基因疗法临床试验进行安全及伦理审查。这项试验还需美国食品和药物管理局放行才能开始实施。如果最终获得批
An advisory committee of the National Institutes of Health approved the first human clinical trial to treat cancer using the CRISPR gene editing technology known as “Gene Scissor ”, leaving the currently attractive biomedical technology in the United States to be clinically The test is shortly approved by the U.S. Food and Drug Administration. The National Institutes of Health “Recombinant DNA Advisory Committee ” approved this clinical trial program submitted by the University of Pennsylvania. The committee is responsible for conducting a safety and ethical review of clinical trials of gene therapy in the United States. The trial still needs to be released by the U.S. Food and Drug Administration to begin its implementation. If eventually approved